Dr. Sara Tolaney @stolaney1.bsky.social shares key take-aways from #ASCO25. #BreastCancer #SERENA6 #MBC #MetasticBreastCancer Watch the video here:
touchoncology.com?p=138380&pos...

15 Posts Not to Miss from the 3rd Day of ASCO 2025 - OncoDaily 15 Posts Not to Miss from the 3rd Day of ASCO 2025 / American Society of Clinical Oncology, Armando Orlandi, ASCO, ASCO 2025, ASCO 25, ATOMIC trial, cancer,

15 Posts Not to Miss from the 3rd Day of ASCO 2025
@ascocancer.bsky.social
@drnataliagandur.bsky.social
@bookiephronesis.bsky.social
@icr.ac.uk
@viveksubbiah.bsky.social ‬

oncodaily.com/societies/as...

#ASCO2025 #ATOMICtrial #Cancer #MATTERHORNtrial #OncoDaily #Oncology #SERENA6 #Veritac2

Program Guide – ASCO Meeting Program Guide

Whether monitoring blood for ctDNA over time improves overall survival through earlier intervention has to be proven. But the best med will always be the one someone is willing to stay on. #SERENA6 meetings.asco.org/abstracts-pr... 5b/8

After two years of follow-up, the new treatment camizestrant improved survival and quality of life for people with metastatic HR+ HER2- breast cancer. Read more about the Serena-6 trial updates here: bit.ly/3FDV4yH
...
#ASCO25 #bcsm #HER2 #breastcancer #breastcancerresearch #serena6

Find a research summary of #SERENA6 at asco.org: Switching to treatment with camizestrant if an ESR1 mutation is detected can slow cancer growth for people with HR+, HER2- advanced #BreastCancer: brnw.ch/21wT4QG
#BCSM

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumou...

Happy to have participated in #SERENA6, using ctDNA to tailor an early switch strategy for metastatic HR+ disease.

Could make ctDNA actually ACTIONable in breast for the first time!

www.astrazeneca.com/media-centre...